semaglutide fda news The approved a pill version of the GLP-1 receptor agonist (Wegovy), making it the first oral GLP-1 agent indicated for weight loss, Novo Nordisk announced on Monday. The once-daily 25 Wegovy® Lawsuit | July 2026

At Aafiyah it is administered intravenously under GP supervision

You can make finer dose adjustments (like stepping from 0.5 mg to 0.75 mg instead of jumping straight to 1.0 mg) and you can use split dosing strategies that pre-filled pens do not allow

Satish A, Punith Kumar R, Rakshith D, Satish S, Ahmed F

More recently, the SELECT trial confirmed cardiovascular benefits of Wegovy in patients with overweight/obesity and established cardiovascular disease without diabetes, leading to its 2024 FDA indication for cardiovascular risk reduction in this population

There have been many medications that have been researched in the treatment of Peyronies